StockData

Inovio Pharmaceuticals vs NeOnc Technologies

INO and NTHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INO and NTHI compare

Inovio Pharmaceuticals is the larger company, worth 1.5 times as much as NeOnc Technologies ($169M against $112M).

Inovio Pharmaceuticals scores higher on the StockData Score (4 against 0 for NeOnc Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINONTHI
Size and price
Market cap$169M$112M
Share price$1.63$4.33
Change, 1 year−20.5%−52.3%
Change, 5 years−98.1%–
Beta (5Y)−0.262.81
Employees275
StockData Score
Total score4 (better)0
Valuation score00
Growth score00
Performance score00
Health score4 (better)0
Dividend score00
Valuation
P/B38.6×–
FCF yield−47.9%–
Growth
Revenue growth (TTM)−100%–
Revenue growth, 5Y average−61.2%–
Profitability
Return on equity−410%–
Financial health
Debt / equity0.00–
Interest coverage–−15.7×
Current ratio1.00 (better)0.38
Altman Z-score−55.23−34.30 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield−22.6%–
Shareholder yield−22.6%0.00% (better)
Ownership
Held by institutions31.7%12.2%
Held by insiders0.38%60.1%
Insider net buying, 12 months–$2.0M
Short interest, % of float21.5%8.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.